What is the difference between the $350 million completed and the new $5 billion authorization?

The $350 million accelerated share repurchase (ASR) was a specific transaction completed during Q4 fiscal 2026 that used a bank to buy shares on Cardinal Health's behalf. The $5 billion authorization is a new Board approval that gives management permission to repurchase up to that amount in the future, under existing Rule 10b-18 or other applicable mechanisms, without requiring new Board approval for each transaction.

Why did Cardinal Health choose an accelerated buyback for the $350 million?

An ASR allows a company to receive shares immediately from a financial institution and settle the transaction over time, typically within a few months. This mechanism locks in a price quickly and is commonly used when a company has high conviction about valuation or wants to reduce share count promptly. The filing does not specify Cardinal Health's rationale, but ASRs are generally preferred when shares are viewed as undervalued.

How much authorization does Cardinal Health have left after the current programs?

As of August 2026, Cardinal Health has $6.4 billion in total share repurchase authorization. The filing does not specify how much of that relates to prior programs versus the new $5 billion increase, but the company has substantial room to repurchase shares without a new Board vote.

What is the expected impact on share count in fiscal 2027?

The company guides to approximately $1 billion in share repurchases in fiscal 2027, which at recent execution rates would reduce share count modestly. The company also guides weighted-average diluted shares outstanding of approximately 233 million for fiscal 2027, compared to 235 million in Q4 2026 and 237 million for full-year 2026, reflecting the ongoing buyback program.

Does Cardinal Health have the cash flow to support both buybacks and dividends?

Yes. Cardinal Health generated $5.0 billion in adjusted free cash flow in fiscal 2026 and guides $3.5 billion to $4.0 billion in fiscal 2027. The company also paid $491 million in dividends in fiscal 2026 and declared a regular quarterly dividend of $0.5158 per share in August 2026. This leaves ample cash for the modest $1 billion fiscal 2027 buyback guidance while maintaining debt management flexibility.

Could the new $5 billion authorization be used for something other than open-market buybacks?

The filing does not specify whether this authorization is limited to open-market purchases under Rule 10b-18 or could include other mechanisms such as tender offers or ASRs. Cardinal Health has already used ASRs (as evidenced by the $350 million program) and may use various execution mechanisms under the authorization, subject to Board policy and market conditions.

CAH 8-K Filed 2026-08-11 New authorization

Cardinal Health approves $5B share repurchase; completes $350M accelerated buyback

Board authorization expands total program to $6.4B; company repurchased $1.4B in fiscal 2026

Authorization$5.0B

Remaining$6.4B

MechanismAccelerated Share Repurchase

What the filing says

Cardinal Health's Board of Directors has approved a $5.0 billion increase to its share repurchase authorization, bringing the total authorization to $6.4 billion as of August 2026. The company simultaneously announced completion of a $350 million accelerated share repurchase (ASR) program during the fourth quarter of fiscal 2026.

In fiscal year 2026, Cardinal Health repurchased a total of $1.4 billion in shares, reflecting strong cash generation. The company reported fiscal year 2026 operating cash flow of $5.2 billion and adjusted free cash flow of $5.0 billion. For fiscal 2027, the company expects to repurchase approximately $1 billion in shares and guides non-GAAP adjusted free cash flow of $3.5 billion to $4.0 billion.

The timing of this authorization comes as Cardinal Health reported strong fourth-quarter and full-year results, with fiscal 2026 revenues of $254.2 billion (up 14% year-over-year) and non-GAAP diluted EPS of $11.26 (up 37% from prior year, or 33% excluding a one-time IEEPA tariff refund benefit). The company provided fiscal 2027 non-GAAP EPS guidance of $12.40 to $12.60, representing 13% to 15% growth.

Cardinal Health recently completed an additional $350 million accelerated share repurchase program, bringing year-to-date share repurchases in fiscal year 2026 to $1.4 billion. Cardinal Health Board of Directors approved a $5.0 billion increase to the share repurchase program, bringing the total share repurchase authorization to $6.4 billion as of August 2026. — CARDINAL HEALTH INC 8-K filing · View on SEC EDGAR →

What this means

The $5 billion authorization significantly expands Cardinal Health's capital return program and signals management confidence in the company's ability to generate cash while maintaining financial flexibility. Combined with the $1.4 billion repurchased in fiscal 2026, the company is actively managing its share count—weighted-average diluted shares declined from 240 million in Q4 2025 to 235 million in Q4 2026. The guidance for approximately $1 billion in repurchases in fiscal 2027 (modest compared to the new authorization) indicates the company may prioritize debt reduction, acquisitions, or other capital deployment while maintaining an opportunistic buyback posture. The $6.4 billion total authorization provides multi-year capacity for share reduction.

Frequently asked questions

What is the difference between the $350 million completed and the new $5 billion authorization?: The $350 million accelerated share repurchase (ASR) was a specific transaction completed during Q4 fiscal 2026 that used a bank to buy shares on Cardinal Health's behalf. The $5 billion authorization is a new Board approval that gives management permission to repurchase up to that amount in the future, under existing Rule 10b-18 or other applicable mechanisms, without requiring new Board approval for each transaction.
Why did Cardinal Health choose an accelerated buyback for the $350 million?: An ASR allows a company to receive shares immediately from a financial institution and settle the transaction over time, typically within a few months. This mechanism locks in a price quickly and is commonly used when a company has high conviction about valuation or wants to reduce share count promptly. The filing does not specify Cardinal Health's rationale, but ASRs are generally preferred when shares are viewed as undervalued.
How much authorization does Cardinal Health have left after the current programs?: As of August 2026, Cardinal Health has $6.4 billion in total share repurchase authorization. The filing does not specify how much of that relates to prior programs versus the new $5 billion increase, but the company has substantial room to repurchase shares without a new Board vote.
What is the expected impact on share count in fiscal 2027?: The company guides to approximately $1 billion in share repurchases in fiscal 2027, which at recent execution rates would reduce share count modestly. The company also guides weighted-average diluted shares outstanding of approximately 233 million for fiscal 2027, compared to 235 million in Q4 2026 and 237 million for full-year 2026, reflecting the ongoing buyback program.
Does Cardinal Health have the cash flow to support both buybacks and dividends?: Yes. Cardinal Health generated $5.0 billion in adjusted free cash flow in fiscal 2026 and guides $3.5 billion to $4.0 billion in fiscal 2027. The company also paid $491 million in dividends in fiscal 2026 and declared a regular quarterly dividend of $0.5158 per share in August 2026. This leaves ample cash for the modest $1 billion fiscal 2027 buyback guidance while maintaining debt management flexibility.
Could the new $5 billion authorization be used for something other than open-market buybacks?: The filing does not specify whether this authorization is limited to open-market purchases under Rule 10b-18 or could include other mechanisms such as tender offers or ASRs. Cardinal Health has already used ASRs (as evidenced by the $350 million program) and may use various execution mechanisms under the authorization, subject to Board policy and market conditions.

authorization accelerated-share-repurchase mega-cap healthcare-sector capital-allocation fiscal-2026

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.